Page 1795 - Williams Hematology ( PDFDrive )

1770 Part XI: Malignant Lymphoid Diseases Chapter 107: Myeloma 1771

cytoreduction for the treatment of malignant and nonmalignant hematologic diseases. 531. Morgan GJ, Davies FE, Gregory WM, et al: First-line treatment with zoledronic acid as
Blood 91:756–763, 1998. compared with clodronic acid in multiple myeloma (MRC Myeloma IX): A randomised
506. Garban F, Attal M, Rossi JF, et al: Immunotherapy by non-myeloablative allogeneic controlled trial. Lancet 376:1989–1999, 2010.
stem cell transplantation in multiple myeloma: Results of a pilot study as salvage ther- 532. Morgan GJ, Child JA, Gregory WM, et al: Effects of zoledronic acid versus clodronic
apy after autologous transplantation. Leukemia 15:642–646, 2001. acid on skeletal morbidity in patients with newly diagnosed multiple myeloma (MRC
507. McSweeney PA, Niederwieser D, Shizuru JA, et al: Hematopoietic cell transplantation Myeloma IX): Secondary outcomes from a randomised controlled trial. Lancet Oncol
in older patients with hematologic malignancies: Replacing high-dose cytotoxic ther- 12:743–752, 2011.
apy with graft-versus-tumor effects. Blood 97:3390–3400, 2001. 533. Woo SB, Hellstein JW, Kalmar JR: Narrative [corrected] review: Bisphosphonates and
508. Michallet M, Bilger K, Garban F, et al: Allogeneic hematopoietic stem-cell transplan- osteonecrosis of the jaws. Ann Intern Med 144:753–761, 2006.
tation after nonmyeloablative preparative regimens: Impact of pretransplantation and 534. Dimopoulos MA, Kastritis E, Bamia C, et al: Reduction of osteonecrosis of the jaw
posttransplantation factors on outcome. J Clin Oncol 19:3340–3349, 2001. (ONJ) after implementation of preventive measures in patients with multiple myeloma
509. Mohty M, Fegueux N, Exbrayat C, et al: Reduced intensity conditioning: Enhanced treated with zoledronic acid. Ann Oncol 20:117–120, 2009.
graft-versus-tumor effect following dose-reduced conditioning and allogeneic trans- 535. Dudeney S, Lieberman IH, Reinhardt MK, et al: Kyphoplasty in the treatment of oste-
plantation for refractory lymphoid malignancies after high-dose therapy. Bone Marrow olytic vertebral compression fractures as a result of multiple myeloma. J Clin Oncol
Transplant 28:335–339, 2001. 20:2382–2387, 2002.
510. Bensinger WI, Maloney D, Storb R: Allogeneic hematopoietic cell transplantation for 536. Fourney DR, Schomer DF, Nader R, et al: Percutaneous vertebroplasty and kyphoplasty
multiple myeloma. Semin Hematol 38:243–249, 2001. for painful vertebral body fractures in cancer patients. J Neurosurg 98:21–30, 2003.
511. Kroger N, Schwerdtfeger R, Kiehl M, et al: Autologous stem cell transplantation fol- 537. Featherstone C, Delaney G, Jacob S, et al: Estimating the optimal utilization rates of
lowed by a dose-reduced allograft induces high complete remission rate in multiple radiotherapy for hematologic malignancies from a review of the evidence: Part II-leu-
myeloma. Blood 100:755–760, 2002. kemia and myeloma. Cancer 103:393–401, 2005.
512. Bruno B, Rotta M, Patriarca F, et al: A comparison of allografting with autografting for 538. Facon T, Mary JY, Hulin C, et al: Melphalan and prednisone plus thalidomide versus
newly diagnosed myeloma. N Engl J Med 356:1110–1120, 2007. melphalan and prednisone alone or reduced-intensity autologous stem cell transplanta-
513. Bruno B, Rotta M, Patriarca F, et al: Nonmyeloablative allografting for newly diagnosed tion in elderly patients with multiple myeloma (IFM 99–06): A randomised trial. Lancet
multiple myeloma: The experience of the Gruppo Italiano Trapianti di Midollo. Blood 370:1209–1218, 2007.
113:3375–3382, 2009. 539. Palumbo A, Ambrosini MT, Benevolo G, et al: Bortezomib, melphalan, prednisone, and
514. Garban F, Attal M, Michallet M, et al: Prospective comparison of autologous stem thalidomide for relapsed multiple myeloma. Blood 109:2767–2772, 2007.
cell transplantation followed by dose-reduced allograft (IFM99–03 trial) with tandem 540. Zangari M, Saghafifar F, Mehta P, et al: The blood coagulation mechanism in multiple
autologous stem cell transplantation (IFM99–04 trial) in high-risk de novo multiple myeloma. Semin Thromb Hemost 29:275–282, 2003.
myeloma. Blood 107:3474–3480, 2006. 541. Auwerda JJ, Sonneveld P, de Maat MP, et al: Prothrombotic coagulation abnormali-
515. Krishnan A, Pasquini MC, Logan B, et al: Tandem autologous stem cell transplants ties in patients with newly diagnosed multiple myeloma. Haematologica 92:279–280,
(auto-auto) with or without maintenance therapy versus single autologous transplant 2007.
followed by HLA-matched sibling non-myeloablative allogeneic stem cell transplant 542. Johnson DC, Corthals S, Ramos C, et al: Genetic associations with thalidomide medi-
(auto-allo) for patients (pts) with high risk (HR) multiple myeloma (MM): Results from ated venous thrombotic events in myeloma identified using targeted genotyping. Blood
the Blood and Marrow Transplant Clinical Trials Network (BMT-CTN) 0102 Trial. 112:4924–4934, 2008.
Blood (ASH Annual Meeting Abstracts) 116:Abstract 526, 2010. 543. Zangari M, Barlogie B, Cavallo F, et al: Effect on survival of treatment-associated
516. Krishnan A, Pasquini MC, Logan B, et al: Autologous haemopoietic stem-cell trans- venous thromboembolism in newly diagnosed multiple myeloma patients. Blood
plantation followed by allogeneic or autologous haemopoietic stem-cell transplantation Coagul Fibrinolysis 18:595–598, 2007.
in patients with multiple myeloma (BMT CTN 0102): A phase 3 biological assignment 544. Morgan GJ, Schey SA, Wu P, et al: Lenalidomide (Revlimid), in combination with
trial. Lancet Oncol 12:1195–1203, 2011. cyclophosphamide and dexamethasone (RCD), is an effective and tolerated regimen
517. Bjorkstrand B, Iacobelli S, Hegenbart U, et al: Tandem autologous/reduced-intensity for myeloma patients. Br J Haematol 137:268–269, 2007.
conditioning allogeneic stem-cell transplantation versus autologous transplantation in 545. Baglin T, Luddington R, Brown K, et al: Incidence of recurrent venous thromboem-
myeloma: Long-term follow-up. J Clin Oncol 29:3016–3022, 2011. bolism in relation to clinical and thrombophilic risk factors: Prospective cohort study.
518. Crawley C, Lalancette M, Szydlo R, et al: Outcomes for reduced-intensity allogeneic Lancet 362:523–526, 2003.
transplantation for multiple myeloma: An analysis of prognostic factors from the 546. Argyriou AA, Iconomou G, Kalofonos HP: Bortezomib-induced peripheral neurop-
Chronic Leukaemia Working Party of the EBMT. Blood 105:4532–4539, 2005. athy in multiple myeloma: A comprehensive review of the literature. Blood 112:1593–
519. Cavo M, Terragna C, Martinelli G, et al: Molecular monitoring of minimal residual 1599, 2008.
disease in patients in long-term complete remission after allogeneic stem cell transplan- 547. Richardson PG, Sonneveld P, Schuster MW, et al: Reversibility of symptomatic periph-
tation for multiple myeloma. Blood 96:355–357, 2000. eral neuropathy with bortezomib in the phase III APEX trial in relapsed multiple mye-
520. Martinelli G, Terragna C, Zamagni E, et al: Molecular remission after allogeneic or loma: Impact of a dose-modification guideline. Br J Haematol 144:895–903, 2009.
autologous transplantation of hematopoietic stem cells for multiple myeloma. J Clin 548. Mileshkin L, Stark R, Day B, et al: Development of neuropathy in patients with mye-
Oncol 18:2273–2281, 2000. loma treated with thalidomide: Patterns of occurrence and the role of electrophysio-
521. Willems P, Verhagen O, Segeren C, et al: Consensus strategy to quantitate malignant logic monitoring. J Clin Oncol 24:4507–4514, 2006.
cells in myeloma patients is validated in a multicenter study. Belgium-Dutch Hematol- 549. Plasmati R, Pastorelli F, Cavo M, et al: Neuropathy in multiple myeloma treated with
ogy-Oncology Group. Blood 96:63–70, 2000. thalidomide: A prospective study. Neurology 69:573–581, 2007.
522. Alyea EP, Soiffer RJ, Canning C, et al: Toxicity and efficacy of defined doses of CD4(+) 550. Pei XY, Dai Y, Grant S: Synergistic induction of oxidative injury and apoptosis in
donor lymphocytes for treatment of relapse after allogeneic bone marrow transplant. human multiple myeloma cells by the proteasome inhibitor bortezomib and histone
Blood 91:3671–3680, 1998. deacetylase inhibitors. Clin Cancer Res 10:3839–3852, 2004.
523. Verdonck LF, Lokhorst HM, Dekker AW, et al: Graft-versus-myeloma effect in two 551. Landowski TH, Megli CJ, Nullmeyer KD, et al: Mitochondrial-mediated disregulation
cases. Lancet 347:800–801, 1996. of Ca2+ is a critical determinant of Velcade (PS-341/bortezomib) cytotoxicity in mye-
524. Alyea E, Weller E, Schlossman R, et al: T-cell–depleted allogeneic bone marrow trans- loma cell lines. Cancer Res 65:3828–3836, 2005.
plant followed by donor lymphocyte infusion in patients with multiple myeloma: 552. Dikic I, Crosetto N, Calatroni S, et al: Targeting ubiquitin in cancers. Eur J Cancer
Induction of graft-versus-myeloma effect. Blood 98:934–939, 2001. 42:3095–3102, 2006.
525. van Rhee F: Con: Allogeneic transplantation in multiple myeloma. Clin Adv Hematol 553. Badros A, Goloubeva O, Dalal JS, et al: Neurotoxicity of bortezomib therapy in multiple
Oncol 4:391–394, 2006. myeloma: A single-center experience and review of the literature. Cancer 110:1042–
526. Berenson J: Pamidronate in the treatment of osteolytic bone lesions in multiple 1049, 2007.
myeloma patients—The American experience. Br J Clin Pract Suppl 87:5–7; discussion 554. Caravita TP, Spagnoli M, A, et al: Neuropathy in multiple myeloma patients treated
13–14, 1996. with bortezomib: A multicenter experience. Blood Abstract 4823, 2007.
527. Rosen LS, Gordon D, Kaminski M, et al: Zoledronic acid versus pamidronate in the 555. Richardson PG, Briemberg H, Jagannath S, et al: Frequency, characteristics, and revers-
treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of ibility of peripheral neuropathy during treatment of advanced multiple myeloma with
multiple myeloma: A phase III, double-blind, comparative trial. Cancer J 7:377–387, bortezomib. J Clin Oncol 24:3113–3120, 2006.
2001. 556. Chen CI, Kouroukis CT, White D, et al: Bortezomib is active in patients with untreated
528. Major P, Lortholary A, Hon J, et al: Zoledronic acid is superior to pamidronate in the or relapsed Waldenström’s macroglobulinemia: A phase II study of the National Cancer
treatment of hypercalcemia of malignancy: A pooled analysis of two randomized, con- Institute of Canada Clinical Trials Group. J Clin Oncol 25:1570–1575, 2007.
trolled clinical trials. J Clin Oncol 19:558–567, 2001. 557. Moreau P, Pylypenko H, Grosicki S, et al: Subcutaneous versus intravenous administra-
529. Terpos E, Morgan G, Dimopoulos MA, et al: International Myeloma Working Group tion of bortezomib in patients with relapsed multiple myeloma: A randomised, phase 3,
recommendations for the treatment of multiple myeloma-related bone disease. J Clin non-inferiority study. Lancet Oncol 12:431–440, 2011.
Oncol 31:2347–2357, 2013. 558. Richardson P, Schlossman R, Jagannath S, et al: Thalidomide for patients with relapsed
530. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in multiple myeloma after high-dose chemotherapy and stem cell transplantation: Results
Oncology Multiple Myeloma. Version 2.2010, 2014. http://www.nccn.org/professionals/ of an open-label multicenter phase 2 study of efficacy, toxicity, and biological activity.
physician_gls/pdf/myeloma.pdf. Last accesse August 2015. Mayo Clin Proc 79:875–882, 2004.

Kaushansky_chapter 107_p1733-1772.indd 1770 9/21/15 12:36 PM